Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
realcool, don't hold your breath. The odds of En Banc r slim to none! As it was pointed out to me earlier by marjac 20-1723 was affirmed. See Fed. Cir. R. 36., google the meaning. It's so final that there is no black and white, no opinions to support any possibility of en banc.
Raf, Thank you for all you do, I hope JT listens to your words of wisdom.
invest, ok Thanks! It's on it's way. I'll credit your alias name invest2992.
invest, if you didn't send this email to Elisabeth I will!
BB, re the last part of your post: Where do I sign up?
It was very bad strategy to piss of CAFC with request to consolidate when OA where already scheduled. Look for JT and Kennedy to be fired soon.
BB
jk:
Amarin needs to find a BP to partner with assuming they get EU approval. I'm discussed with this company the En Banc filing will get thrown out so fast it'll make their heads spin. They need to sell what's left of the company and go home. The best news we can get is that they've retained a banker to help them move forward.
30 days to file a petition for En Banc review. So is this a good thing? Or a waste of time and money?
BRIEF-Amarin Provides Update Following Ruling In Vascepa ANDA Patent Litigation
REUTERS 10:57 AM ET 9/3/2020
Symbol Last Price Change
AMRN 4.84down -0.2 (-3.97%)
QUOTES AS OF 11:04:43 AM ET 09/03/2020
Sept 3 (Reuters) - Amarin Corporation PLC(AMRN):
* AMARIN PROVIDES UPDATE FOLLOWING RULING IN VASCEPA® ANDA PATENT LITIGATION
* AMARIN(AMRN) - CURRENTLY REVIEWING ITS LEGAL OPTIONS AND WITHIN 30 DAYS EXPECTS TO FILE A PETITION FOR AN EN BANC REVIEW OF CURRENT PANEL DECISION
* AMARIN CORPORATION PLC(AMRN) - INTENDS TO CONTINUE CURRENT PROMOTION LEVELS OF VASCEPA IN UNITED STATES
* AMARIN CORPORATION PLC(AMRN) - ANTICIPATES THAT GENERICS COMPANIES, WHEN THEY LAUNCH IN U.S., ARE LIKELY TO HAVE LIMITED SUPPLY CAPACITY FOR VASCEPA Source text for Eikon: Further company coverage:
(c) Copyright Thomson Reuters 2020. Click For Restrictions - https://agency.reuters.com/en/copyright.html
money, one more try LOL
http://www.cafc.uscourts.gov/node/26552
maybe copy and paste?? sorry
Hopefully the below will open in listen mode???
U.S. Court of Appeals for the Federal Circuit <uscourts@updates.uscourts.gov>
If anyone cares to listen to OA again, pls see link below.
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA
There's an old saying in wall street, NEVER avg down, if anything average up. But what do I know I only hedged 1/3 of my position.
Awful day for us Amarinians
GLTA
Raf, yeah who do you believe? There are no tangibles, just all air "cloud" talk. Just imagine when Ai takes over, the world will be one big TikTok.
Amen!!
Marj, From your lips to God's ear...
Raf - no luck of the Irish here!!
BB call in #409-207-6995 code#8333853 starts at 9 am. Recommended call in time NO later than 9:45am est.
GLTA
Chris, would it be possible to post the entire article?
Chris, thanks so much for your Bloomberg post. Fingers et al crossed!
Wonder if Leland is still working at OPCO???
Analyst Actions: Oppenheimer Downgrades Acasti Pharma to Perform From Outperform as T2 Disappoints on High Placebo Response
MT NEWSWIRES 10:42 AM ET 9/1/2020
Symbol Last Price Change
ACST 0.2319down -0.0128 (-5.23%)
QUOTES AS OF 10:42:48 AM ET 09/01/2020
10:42 AM EDT, 09/01/2020 (MT Newswires) -- Wall Street price targets on Acasti Pharma(ACST) range from $0.50 to $7.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Price: 0.23, Change: -0.01, Percent Change: -5.60
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
KG, if you check the avg vol for the jan 15 30 strike you'll note that there hasn't been much vol for months in comparison to over 300 options yesterday, it's considered a fairly active day.
sts66
That would just clutter up their phone lines, not affect access to trading apps - and if you don't know what a stock split does you shouldn't be buying stocks!
When you say "you" are you addressing me or the general public. I usually don't take posts personally but you should never question my responses when I reply to a stock market. If I'm not 100% sure of my posts I remain silent. Just sayin....
sts, besides technical difficulties brokerage firms have been inundated with questions from shareholders about tsla and aapl splits.
dml, agreed, I have an interest in the Jan 15 2021, $30 strike vol has exploded
advfn, exactly my reaction to meowbot's post, wtf???
dtg, Thanks
I have the original matrix created by Capt Bear's from the end of June. Order of names has changed???
dtg,
Thanks for your post. Whoever (won't mention name) is the admin for the private FB group is definitely not user friendly. He booted several people out of the group if they aren't on the same page as he is....so happy that IHub admins are more diplomatic.
jomama, I don't believe OA are considered a material event, when the company announces the results of the appeal then the stock will be halted as it's a material event. OA will be a matter of interpretation amongst the legal beagles. Unless the stock trades erratically based on a formula set forth by the rules of Nasdaq, it may trigger a halt for a while but it's unlikely.
I hope that helps with your question.
BB, Where are all the naysayers? AF, MRC, MH, Dr Nissan etc.
couldbe, AMEN to your words of wisdom!
HK, you are brilliant, bar none. Thank you
meow, lol, thx for your interpretation of the "Dyk" lol missteps.
pls ignore last post, wrong publication
momo, what does this mean in layman's terms?
north, post #293221 CHris 2125 posted update, but no charts.
Chris, thanks for posting.
Excuse me. Yaseen Rohimi is a well respected woman in wall street amongst bio tech analysts.
She is not a HE.
James, I believe your numbers are a little off the mark.
http://hlstherapeutics.investorroom.com/download/MDA+Jun+20+-+Final.pdf